Find out how self-driving labs utilise data-driven approaches to enhance drug discovery efficiency and innovation.

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.

Alfasigma has agreed to buy the global rights to GSK’s experimental liver disease drug in a deal worth up to $690m.

The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as having “best-in-class potential” in a competitive field.

The FDA assigned a PDUFA target action date of December 22, 2026 –– The NDA is based on positive data from a successful clinical program ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

FDA grants priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, after trial shows markedly better recurrence-free survival than T-DM1.

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

AstraZeneca secures US priority review for Enhertu, GSK agrees linerixibat deal with Alfasigma, while AdvancedAdvT rules out M&C Saatchi bid. Here is what you need to know before the London market ...

Researchers report a drug discovery strategy using tailor-made cyclic peptides to target β-arrestins, key regulators of ...